Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19 (NOVELLA)
A Phase II Randomized, Double-blind Study to Evaluate the Safety, Neutralizing Activity and Efficacy of AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants Having an Increased Risk for Inadequate Response to Active Immunization (NOVELLA)
Sponsor: AstraZeneca
A PHASE2 clinical study on COVID-19, SARS-CoV-2, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 9 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Mar 2024 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Sep 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .